Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, net profit 11% to Rs 233 crore
According to IQVIA MAT December 2024 data, Ajanta Pharma’s India growth was 11%, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%.
Ajanta Pharma
Stay updated with the latest news and articles about Ajanta Pharma.
Latest Articles
Ajanta Pharma shares jump 8% on strong Q4 numbers
Ajanta Pharma has also announced buyback of shares worth Rs 285 crore.
Stocks to watch: Adani Enterprises, Vi, Hero MotoCorp, Blue Star and others
Due to a rise in finance and operating expenses, Vodafone India's net loss increased 6.4% year over year (YoY) to Rs 7,595 crore in the second quarter of FY23.
Ajanta Pharma approves buyback worth Rs 135.97 crore
Ajanta Pharma ltd. announced on Wednesday that it would buyback of 7,35,000 equity shares worth Rs 135.97 crore.